Whales with a great deal of cash to invest have actually taken a significantly bullish position on Sarepta Therapies
Taking a look at alternatives history for Sarepta Therapies SRPT we found 38 trades.
If we think about the specifics of each trade, it is precise to state that 50% of the financiers opened trades with bullish expectations and 36% with bearish.
From the general spotted trades, 26 are puts, for an overall quantity of $2,831,990 and 12, calls, for an overall quantity of $551,179.
Today’s Finest Financing Offers
Forecasted Rate Variety
Based upon the trading activity, it appears that the considerable financiers are going for a rate area extending from $20.0 to $70.0 for Sarepta Therapies over the current 3 months.
Insights into Volume & & Open Interest
Analyzing the volume and open interest offers essential insights into stock research study. This details is type in evaluating liquidity and interest levels for Sarepta Therapies’s alternatives at particular strike costs. Listed below, we provide a photo of the patterns in volume and open interest for calls and puts throughout Sarepta Therapies’s considerable trades, within a strike cost series of $20.0 to $70.0, over the previous month.
Sarepta Therapies 30-Day Choice Volume & & Interest Picture
Largest Options Trades Observed:
| Sign | PUT/CALL | Trade Type | Belief | Exp. Date | Ask | Quote | Rate | Strike Rate | Overall Trade Rate | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT | PUT | TRADE | BEARISH | 08/15/25 | $ 25.7 | $ 25.5 | $ 25.7 | $ 45.00 | $ 514.0 K | 9.5 K | 302 |
| SRPT | PUT | TRADE | BULLISH | 08/15/25 | $ 51.3 | $ 49.0 | $ 49.0 | $ 70.00 | $ 490.0 K | 311 | 100 |
| SRPT | PUT | SWEEP | BULLISH | 06/20/25 | $ 14.1 | $ 14.0 | $ 14.0 | $ 35.00 | $ 350.0 K | 2.3 K | 257 |
| SRPT | PUT | TRADE | BULLISH | 08/15/25 | $ 27.2 | $ 25.5 | $ 25.7 | $ 45.00 | $ 257.0 K | 9.5 K | 102 |
| SRPT | PUT | TRADE | BULLISH | 06/27/25 | $ 17.3 | $ 16.4 | $ 16.7 | $ 35.00 | $ 167.0 K | 806 | 212 |
About Sarepta Therapies
Sarepta Therapies Inc is a biotechnology business concentrated on dealing with uncommon, transmittable, and other illness. It targets a broad series of illness while concentrating on the fast advancement of its drug prospects. Sarepta’s includes exclusive RNA-targeted innovation platforms to be utilized for establishing unique pharmaceutical items to deal with a broad series of illness and address essential unmet medical requirements. The business utilizes third-party specialists to make its item prospects. Bulk of business’s item prospects are at an early phase of advancement.
After an extensive evaluation of the alternatives trading surrounding Sarepta Therapies, we transfer to analyze the business in more information. This consists of an evaluation of its existing market status and efficiency.
Sarepta Therapies’s Present Market Status
- Trading volume stands at 29,232,577, with SRPT’s cost down by -41.29%, placed at $21.24.
- RSI indications reveal the stock to be might be oversold.
- Revenues statement anticipated in 51 days.
What Experts Are Stating About Sarepta Therapies
5 market specialists have actually just recently provided scores for this stock, with an agreement target cost of $52.0.
Turn $1000 into $1270 in simply 20 days?
20-year professional alternatives trader exposes his one-line chart method that reveals when to purchase and offer. Copy his trades, which have actually had balanced a 27% earnings every 20 days. Click on this link for gain access to
* An expert from Needham continues with their Buy ranking on Sarepta Therapies, keeping a target cost of $50.
* In a favorable relocation, an expert from Scotiabank has actually updated their ranking to Sector Outperform and changed the cost target to $80.
* Keeping their position, an expert from JP Morgan continues to hold an Obese ranking for Sarepta Therapies, targeting a rate of $84.
* An expert from HC Wainwright & & Co. has actually modified its ranking downward to Offer, changing the cost target to $10.
* In a mindful relocation, an expert from Piper Sandler devalued its ranking to Neutral, setting a rate target of $36.
Alternatives are a riskier possession compared to simply trading the stock, however they have greater earnings capacity. Severe alternatives traders handle this danger by informing themselves daily, scaling in and out of trades, following more than one sign, and following the marketplaces carefully.
If you wish to remain upgraded on the current alternatives trades for Sarepta Therapies, Benzinga Pro offers you real-time alternatives trades informs.